Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease and cancer. Cue Biopharma’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T Cells) and biologics are designed to harness the curative potential of the body’s innate immune system through the selective modulation of disease-relevant T cells without the adverse effects of broad systemic immune activation.
Company Details
- Employees
- 42
- Founded
- 2014
- Address
- 40 Guest Street, Boston,massachusetts 02135,united States
- Phone
- 617-949-2680
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://cuebiopharma.com
- HQ
- Boston, Massachusetts
Cue Biopharma Questions
Cue Biopharma's helpline number is 617-949-2680
Cue Biopharma's website is http://cuebiopharma.com
Cue Biopharma's LinkedIn profile is https://www.linkedin.com/company/cuebiopharma
Cue Biopharma has
42 employees.
View email and phone details for 42
employees at Cue Biopharma.
Cue Biopharma's industry is
Biotechnology Research
Cue Biopharma's top competitors are
Bioage Labs,
Ventyx Biosciences,
858 Therapeutics,
Route 92 Medical,
Mdxhealth,
Longbio Pharma,
Genespire,
Wave Life Sciences,
Lift Biosciences,
Mendaera, Inc..
Cue Biopharma's categories are Biotechnology Research
Cue Biopharma's founding year is 2014
